Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023
04 nov. 2023 10h00 HE
|
Vera Therapeutics
Additional analysis of week 36 data from the Phase 2b ORIGIN study of atacicept demonstrating resolution of hematuria in the majority of IgAN patients.
Vera Therapeutics Scheduled to Present at November Investor Conferences
30 oct. 2023 08h00 HE
|
Vera Therapeutics
BRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting
13 oct. 2023 10h22 HE
|
Vera Therapeutics
Informational poster for ORIGIN 3 Pivotal Phase 3 study evaluating atacicept in IgA Nephropathy (IgAN) Additional analysis of week 36 data from Phase 2b ORIGIN study show atacicept 150mg reduces...
Vera Therapeutics Scheduled to Present at September Investor Conferences
31 août 2023 08h00 HE
|
Vera Therapeutics
BRISBANE, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results
10 août 2023 08h00 HE
|
Vera Therapeutics
Presented positive 36-week results from the Phase 2b ORIGIN clinical trial of atacicept in IgAN as a late breaking clinical trial at the 60th ERA CongressInitiated Phase 3 ORIGIN 3 clinical trial of...
Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress
17 juin 2023 10h10 HE
|
Vera Therapeutics
New data at week 36 shows atacicept 150 mg resulted in a delta of 43% versus placebo in mean proteinuria reduction in per-protocol analysis and demonstrated statistically significant stabilization of...
Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN
15 juin 2023 16h44 HE
|
Vera Therapeutics
BRISBANE, Calif., June 15, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...
Vera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
08 juin 2023 08h00 HE
|
Vera Therapeutics
BRISBANE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (IgAN)
07 juin 2023 08h00 HE
|
Vera Therapeutics
Pivotal Phase 3 Trial for Atacicept in IgA Nephropathy Initiated Today Late-breaking results of ORIGIN Phase 2b trial supporting further evaluation of atacicept 150 mg as a potential...
Vera Therapeutics Provides Business Update and Reports First Quarter Financial Results
11 mai 2023 07h30 HE
|
Vera Therapeutics
36-week data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN selected for presentation as a late breaking clinical trial at ERA Congress 2023 Plan to initiate a pivotal Phase 3 clinical...